免疫检查点抑制剂相关肾炎的影像学特征与临床相关性:活检证实病例的回顾性系列研究
肾炎时总肾脏体积较基线显著增大(464.7 ± 96.8 mL vs. 371.7 ± 187.7 mL;PET-CT上肾实质SUVmax与血池比值在肾炎时显著升高(2.13 vs. 1.68;p = 0.035),而肾盂SUVmax与血池SUVmean比值显著降低(3.47 vs. 8.22;p = 0.011)。
要点
- 免疫检查点抑制剂相关肾炎可表现为双肾体积增大、新发/增多的肾周脂肪条索及双侧楔形低强化皮质灶。
- PET-CT可见肾皮质FDG摄取弥漫性增高及集合系统FDG活性/排泄减少。
- 总肾脏体积增加>30%与更差的肾毒性分级和更积极的临床干预相关。
关键影像表现/征象
- 肾炎时总肾脏体积较基线显著增大(464.7 ± 96.8 mL vs. 371.7 ± 187.7 mL;p < 0.001)。
- 10例(29.4%)肾炎时出现新发/增多的肾周脂肪条索。
- 8例肾炎时行增强CT的患者中,1例(12.5%)出现双侧楔形低强化皮质灶。
- PET-CT上肾实质SUVmax与血池比值在肾炎时较基线显著升高(2.13 vs. 1.68;p = 0.035),肾盂SUVmax与血池SUVmean比值显著降低(3.47 vs. 8.22;p = 0.011)。
临床应用与阅片要点
- 阅片时注意比较双肾体积较基线的变化,总肾脏体积增加>30%提示更重肾毒性和需更积极治疗。
- 关注新发或增多的肾周脂肪条索及双侧楔形低强化皮质灶,结合免疫治疗史提示肾炎可能。
- PET-CT阅片时注意肾皮质FDG摄取弥漫增高及肾盂FDG活性/排泄减少的征象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Imaging appearances of immune checkpoint inhibitor-related nephritis have not yet been described. The primary objective of this study is to describe the appearances of immunotherapy-related nephritis on computerized tomography (CT) and positron emission tomography (PET). The secondary objectives are to investigate the association of radiologic features with clinical outcomes.
METHODS: CT and PET-CT scans before the initiation of immunotherapy (baseline), at nephritis, and after resolution of pathology-proven nephritis cases were reviewed. Total kidney volume, renal parenchymal SUVmax, renal pelvis SUVmax, and blood pool SUVmean were obtained.
RESULTS: Thirty-four patients were included. The total kidney volume was significantly higher at nephritis compared to baseline (464.7 ± 96.8 mL vs. 371.7 ± 187.7 mL; p < 0.001). Fifteen patients (44.1%) had > 30% increase in total kidney volume, which was associated with significantly higher renal toxicity grade (p = 0.007), higher peak creatinine level (p = 0.004), and more aggressive medical treatment (p = 0.011). New/increasing perinephric fat stranding was noted in 10 patients (29.4%) at nephritis. Among 8 patients with contrast-enhanced CT at nephritis, one (12.5%) developed bilateral wedge-shaped hypoenhancing cortical. On PET-CT, the renal parenchymal SUVmax-to-blood pool ratio was significantly higher at nephritis compared to baseline (2.13 vs. 1.68; p = 0.035). The renal pelvis SUVmax-to-blood pool SUVmean ratio was significantly lower at nephritis compared to baseline (3.47 vs. 8.22; p = 0.011).
CONCLUSIONS: Bilateral increase in kidney size, new/increasing perinephric stranding, and bilateral wedge-shaped hypoenhancing cortical foci can occur in immunotherapy-related nephritis. On PET-CT, a diffuse increase in radiotracer uptake throughout the renal cortex and a decrease in radiotracer activity in the renal pelvis can be seen.
KEY POINTS: • CT features of immune checkpoint inhibitor-related nephritis include an increase in kidney volume, new/increasing perinephric stranding, and bilateral ill-defined wedge-shaped hypoenhancing cortical foci. • FDG-PET features of immune checkpoint inhibitor-related nephritis include an increase in FDG uptake throughout the renal cortex and a decrease in FDG activity/excretion in the collecting system. • > 30% increase in total kidney volume is associated with worse toxicity grade and more aggressive medical management.
引用
- Awiwi, Abudayyeh, Abdel-Wahab, et al. Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases. Eur Radiol. 2022. PMID: 36255488. doi:10.1007/s00330-022-09158-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。